Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus

Type 2 diabetes mellitus (T2DM) is closely related to the development of atrial fibrillation (AF), an association that increases cardiovascular morbidity and mortality for patients with diabetes mellitus. 1 Bell DSH Goncalves E. Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab. 2019; 21: 210-217 Crossref PubMed Scopus (60) Google Scholar Although the exact mechanisms remain undetermined, it has been well established over the last decade that T2DM is associated with a significant increase in the risk for AF diagnosis. 2 Huxley RR Filion KB Konety S Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011; 108: 56-62 Abstract Full Text Full Text PDF PubMed Scopus (326) Google Scholar Co-morbid obesity increases the prevalence of AF because of its adverse effects on cardiac structure and function. 3 Lavie CJ Pandey A Lau DH Alpert MA Sanders P. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. J Am Coll Cardiol. 2017; 70: 2022-2035 Crossref PubMed Scopus (198) Google Scholar It has been previously demonstrated that newer antidiabetics have a neutral effect on the risk for AF, while sodium-glucose co-transporter-2 inhibitors may indeed decrease the risk for new-onset AF. 4 Patoulias D Toumpourleka M Papadopoulos C Doumas M. Meta-analysis evaluating the risk of atrial fibrillation with newer antidiabetics across the cardiovascular and renal outcome trials. Am J Cardiol. 2021; 139: 139-141 Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar